David A. Lowe
Scientific advisory board
Pronexus
Sweden
Biography
Lowe is the Founder, CEO & President of NeuroAssets, a leading trans-Atlantic neuroscience consultancy working with Pharma, Biotech and Foundations and private individuals on strategic, operational, scientific, clinical, regulatory, business development and financing aspects of their projects. David has a successful record in neuroscience biotech companies: CSO and EVP PsychoGenics Inc, CSO and Board Director of Memory Pharmaceuticals (acquired by Hoffman-La Roche Inc), EVP and Founding CSO of Fidelity Biosciences, and President and CEO EnVivo Pharmaceuticals Inc (now Forum Pharmaceuticals, a Fidelity Company). Earlier in his career David headed large CNS R&D groups in Pharma at Sandoz Ltd (now Novartis), Bayer and Roche. Dr. Lowe’s experience includes private and public companies as well as venture capital. He has more than 35 years’ experience in CNS drug discovery, translational medicine and product development, initiating and implementing collaborations between Pharma, Biotech, and Academia, with an established track record of generating diverse clinical candidates that moved into clinical trials and the market. He is also Adjunct Professor of Neuroscience at the Icahn School of Medicine in New York
Research Interest
He has more than 35 years’ experience in CNS drug discovery, translational medicine and product development
